Donislecel

Donislecel
Clinical data
Trade namesLantidra
Other namesdonislecel-jujn
License data
Routes of
administration		Islet cell transplantation via intravenous infusion
ATC code
Legal status
Legal status
Identifiers
KEGG

Donislecel, sold under the brand name Lantidra, is a cellular therapy medication used for the treatment of type 1 diabetes. Donislecel is an allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells. Donislecel is administered as a single infusion into the hepatic (liver) portal vein.

The most common adverse reactions include nausea, fatigue, anemia, diarrhea, and abdominal pain.

Donislecel was approved for medical use in the United States in June 2023.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.